Harrison.ai Open Platform Welcomes New AI Partners
Four new AI partners — AIRAmed, Koios Medical, Lunit, and Nanox AI — have joined the Harrison.ai Open Platform, expanding the range of AI solutions available to healthcare organisations worldwide.
Why We Built the Open Platform
When we launched the Open Platform, our goal was straightforward: give healthcare organisations genuine choice in how they adopt medical imaging AI – without the hidden costs, vendor lock-in, or opaque pricing that can slow adoption.
The platform was built on an open architecture model with a customer ROI-first approach. That means zero mark-ups to vendors, no blocking of competing applications that meet industry-standard containerisation specifications, and a single integration point into existing PACS, RIS, and EHR systems. Once connected, organisations can access a growing catalogue of AI applications, curated based on real customer needs and expanded as those needs evolve.
We believe the best AI for a given patient population or workflow should win on merit — not limited to commercial barriers. As Dr. Tobias Lindig, CEO of AIRAmed, puts it: “Open ecosystems are essential for the scalable and responsible adoption of medical AI. Healthcare providers should have the flexibility to select best-in-class solutions without commercial barriers or mark-ups.”
Introducing Our New Partners
Each of our new partners brings deep expertise across different imaging modalities and clinical domains, helping healthcare organisations find the right tools for their specific needs:
- AIRAmed
Specialising in quantitative MRI analysis for the early detection and monitoring of neurodegenerative diseases, including Alzheimer’s and multiple sclerosis. CE-certified and FDA-cleared, AIRAmed’s solutions are clinically deployed at leading institutions internationally. - Koios Medical
Koios Medical develops medical device software to assist physicians interpreting ultrasound images, applying deep machine learning to reach accurate diagnoses. The Koios DS SmartUltrasoundTM platform is focused on breast and thyroid cancer diagnosis, using advanced AI algorithms to assist in early disease detection while reducing recommendations for biopsy of benign tissue. - Lunit
Founded in 2013, Lunit is a global leader in AI for cancer diagnostics and precision oncology, delivering clinically validated software for early detection, risk assessment, and efficient screening. Its breast cancer screening ecosystem covers imaging quality, breast density, cancer detection, and patient management—supporting confident, personalised care decisions. - Nanox AI
Nanox.AI solutions analyse routine CT scans for any clinical indication to help identify patients with asymptomatic or undetected findings correlated with chronic conditions in in cardiac, bone (FDA-cleared and CE-marked), and liver (FDA-cleared), promoting preventive care management.
Together, these additions mean the Harrison.ai Open Platform now covers a broad spectrum of AI solutions across X-ray, CT, MRI, mammography, and ultrasound – complementing our own native solutions with specialist tools from across the industry.
See how Harrison.ai Open Platform could work for your organisation.
What This Means for Healthcare Organisations
Medical imaging AI is no longer a question of if, it’s a question of which, how, and for whom. Every health system has different workflows, patient populations, and strategic priorities. The right algorithm for a large urban teaching hospital may not be the right algorithm for a regional imaging centre.
The Harrison.ai Open Platform is designed for exactly this reality. Healthcare organisations can evaluate AI tools across vendors in a single environment, with full transparency around pricing and value. There’s no need to negotiate separate integrations for each solution or manage multiple vendor relationships in isolation. Brandon Suh, CEO of Lunit, describes the opportunity well: “The Harrison Open Platform offers an exceptional foundation for Lunit’s solutions to be surfaced to customers in key markets.”
As global adoption of medical imaging AI continues to accelerate, the Open Platform will continue to evolve — adding new partners, expanding modality coverage, and supporting healthcare organisations as their needs grow and change. For partners like Nanox, the scale this unlocks is a key part of the value proposition. As Erez Meltzer, CEO and Acting Chairman of Nanox, notes: “We are expanding Nanox’s commercial footprint by bringing AI solutions with demonstrated real-world value to healthcare providers at scale, supported by Harrison.ai’s deployment across more than 1,000 healthcare sites worldwide.”
As Chad McClennan, President & CEO of Koios Medical, states: “We could not be happier to be working closely and aligned with our colleagues at Harrison.ai.” The feeling is mutual — and reflects the spirit with which we’ve approached every partnership on the Open Platform. We’re proud to be working alongside organisations that share our commitment to putting clinicians and patients first.
Harrison.ai develops comprehensive radiology AI that helps clinicians see more and miss less. With 3,400+ clinicians using our tools, Harrison.ai has impacted more than 7 million patients’ lives to date.
Want to Learn More?
If you’re exploring how medical imaging AI could fit into your organisation’s workflows, or you’d like to understand how the Open Platform could consolidate your AI strategy with one integration, we’d love to talk.
Simplify your AI strategy without compromising on choice.
